Find Reports

Select Report Type

Reimbursement Review

Displaying 201 - 225 of 1258

Please scroll or swipe to the right to view the full content.

Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
Nexviazyme	avalglucosidase alfa	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder Feedback on Draft Recommendation	Pompe disease	Reimburse with clinical criteria and/or conditions	Complete	Sep 30, 2021	Jul 5, 2022	SR0703-000
Retevmo	selpercatinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder Feedback on Draft Recommendation	Thyroid cancer	Reimburse with clinical criteria and/or conditions	Complete	Oct 29, 2021	Jun 29, 2022	PC0274-000
Breyanzi	lisocabtagene maraleucel	Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder feedback on Draft Recommendation	Relapsed or refractory large B-cell lymphoma	Reimburse with clinical criteria and/or conditions	Complete	Aug 9, 2021	Jun 29, 2022	PG0258-000
Lenvima and Keytruda	lenvatinib and pembrolizumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	advanced or metastatic renal cell carcinoma	Reimburse with clinical criteria and/or conditions	Complete	Nov 15, 2021	Jun 23, 2022	PC0268-000
Oxervate	cenegermin	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder Feedback on Draft Recommendation	Neurotrophic keratitis	Reimburse with clinical criteria and/or conditions	Complete	Oct 29, 2021	Jun 23, 2022	SR0704-000
Vyndaqel	tafamidis	Recommendation and Reasons Request for Advice Report Stakeholder feedback on Draft Recommendation	Transthyretin-mediated amyloidosis	Reimburse with clinical criteria and/or conditions	Complete	Dec 14, 2021	Jun 17, 2022	SF0722-000
Trikafta	elexacaftor/tezacaftor/ivacaftor and ivacaftor	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder Feedback on Draft Recommendation	Cystic fibrosis, F508del CFTR mutation, 6 years and older	Reimburse with clinical criteria and/or conditions	Complete	Nov 5, 2021	Jun 17, 2022	SR0710-000
Firdapse	amifampridine phosphate	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Lambert-Eaton Myasthenic Syndrome, adults	Reimburse with clinical criteria and/or conditions	Complete	Nov 15, 2021	Jun 16, 2022	SR0664-000
HyQvia	immune globulin human and recombinant human hyaluronidase	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Stakeholder feedback on Draft Recommendation	Humoral immunodeficiency	Reimburse with clinical criteria and/or conditions	Complete	Jun 24, 2021	Jun 15, 2022	ST0695-000
Rinvoq	upadacitinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	atopic dermatitis	Reimburse with clinical criteria and/or conditions	Complete	Apr 13, 2021	Jun 8, 2022	SR0685-000
Libtayo	cemiplimab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Non-small cell lung cancer	Reimburse with clinical criteria and/or conditions	Complete	Oct 13, 2021	Jun 2, 2022	PC0262-000
Osphena	ospemifene	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Dyspareunia, vaginal dryness	Reimburse with clinical criteria and/or conditions	Complete	Oct 26, 2021	May 13, 2022	SR0709-000
Retevmo	selpercatinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder Feedback on Draft Recommendation	RET fusion-positive non-small cell lung cancer	Reimburse with clinical criteria and/or conditions	Complete	Aug 17, 2021	Apr 28, 2022	PC0261-000
Qinlock	ripretinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Gastrointestinal stromal tumours	Reimburse with clinical criteria and/or conditions	Complete	Oct 15, 2021	Apr 28, 2022	PC0265-000
Intrarosa	prasterone	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Postmenopausal vulvovaginal atrophy	Reimburse with clinical criteria and/or conditions	Complete	Oct 1, 2021	Apr 14, 2022	SR0707-000
Zemaira	Alpha1-proteinase inhibitor (Human)	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder Feedback on Draft Recommendation	Severe Alpha1-proteinase inhibitor deficiency	Reimburse with clinical criteria and/or conditions	Complete	Oct 1, 2021	Apr 13, 2022	ST0702-000
Tavalisse	fostamatinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Chronic immune thrombocytopenia	Do not reimburse	Complete	Jul 22, 2021	Apr 5, 2022	SR0701-000
Bimzelx	bimekizumab	Recommendation and Reasons: Updated Recommendation and Reasons: Original Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Psoriasis, moderate to severe plaque	Reimburse with clinical criteria and/or conditions	Complete	Aug 17, 2021	Mar 30, 2022	SR0698-000
Pemazyre	pemigatinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Stakeholder feedback on Draft Recommendation	Cholangiocarcinoma	Do not reimburse	Complete	Jun 23, 2021	Mar 23, 2022	PC0252-000
Lorbrena	lorlatinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	ALK-positive locally advanced or metastatic non-small cell lung	Reimburse with clinical criteria and/or conditions	Complete	Jun 18, 2021	Mar 17, 2022	PC0249-000
Ngenla	somatrogon	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder Feedback on Draft Recommendation	Growth hormone deficiency	Reimburse with clinical criteria and/or conditions	Complete	Jun 3, 2021	Mar 8, 2022	SR0683-000
Myinfla	colchicine	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Atherothrombotic events in coronary artery disease	Do not reimburse	Complete	May 28, 2021	Mar 8, 2022	SR0691-000
Adtralza	tralokinumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Clinician Input Stakeholder feedback on Draft Recommendation	atopic dermatitis	Do not reimburse	Complete	Apr 27, 2021	Mar 7, 2022	SR0689-000
Opdivo	nivolumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder Feedback on Draft Recommendation	Gastroesophageal junction or esophageal adenocarcinoma	Reimburse with clinical criteria and/or conditions	Complete	Aug 18, 2021	Mar 4, 2022	PC0259-000
Libtayo	cemiplimab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Basal cell carcinoma	Reimburse with clinical criteria and/or conditions	Complete	Aug 19, 2021	Mar 4, 2022	PC0260-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 201 - 225 of 589

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Post‒COVID-19 Condition: A Condition-Level Review	Post-COVID 19 Condition (Long COVID) Scoping Summary	Jan 15, 2023	Condition Level Review	Completed	HL0001-000
Identifying Overused Lab Tests in Hospital Settings: A Delphi Study	Identifying Overused Lab Tests in Hospital Settings: A Delphi Study	Jan 13, 2023	Environmental Scan	Completed	ES0362-000
Copper and Ceruloplasmin Tests for Children With Global Developmental Delay and Intellectual Disability	Copper and Ceruloplasmin Tests for Children With Global Developmental Delay and…	Jan 9, 2023	Rapid Review	Completed	RC1467-000
Community Supports for People with Tuberculosis	Community Supports for People with Tuberculosis	Jan 4, 2023	Technology Review	Completed	HC0051-000
Transition from alteplase (tPA) to tenecteplase (TNK) for thrombolysis for acute ischemic stroke		Dec 23, 2022	Policy Insight	In Progress	CY0015-000
Bevacizumab for the Treatment of Patients with Brain Radionecrosis	Bevacizumab for the Treatment of Patients with Brain Radionecrosis	Dec 6, 2022	Rapid Review	Completed	RC1465-000
Subtypes of Post-COVID-19 Condition	Subtypes of Post-COVID-19 Condition	Dec 5, 2022	Technology Review	Completed	HC0035-000
Oseltamivir for the Prevention of Influenza in Residents of Long-Term Care Facilities	Oseltamivir for the Prevention of Influenza in Residents of Long-Term Care Faci…	Nov 29, 2022	Rapid Review	Completed	RC1464-000
Octreotide Long-Acting Release and Everolimus for Recurrent Meningiomas	Octreotide Long-Acting Release and Everolimus for Recurrent Meningiomas	Nov 23, 2022	Rapid Review	Completed	RC1462-000
Body Mass Index as a Measure of Obesity and Cut-off for Surgical Eligibility	Body Mass Index as a Measure of Obesity and Cut-off for Surgical Eligibility	Nov 16, 2022	Technology Review	Completed	HC0048-000
Treatment Options for VEXAS Syndrome	Treatment Options for VEXAS Syndrome	Nov 11, 2022	Rapid Review	Completed	RC1460-000
Intravenous Iron Preparations for Patients Undergoing Elective Surgery: A 2022 Update	Intravenous Iron Preparations for Patients Undergoing Elective Surgery: A 2022 …	Nov 9, 2022	Rapid Review	Completed	RC1457-000
Peer Support Programs for Youth Mental Health	Peer Support Programs for Youth Mental Health - Technology Review Project Protocol Included Studies List	Nov 8, 2022	Health Technology Assessment	Completed	HT0036-000
Raltitrexed in patients with dihydropyrimidine dehydrogenase (DPD) deficiency	Raltitrexed in patients with dihydropyrimidine dehydrogenase (DPD) deficiency	Nov 7, 2022	Reference List	Completed	RC1463-000
Transanal Total Mesorectal Excision for Adult Patients with Rectal Cancer	Transanal Total Mesorectal Excision for Adult Patients with Rectal Cancer	Nov 7, 2022	Rapid Review	Completed	RC1459-000
Liposuction for Lymphedema	Liposuction for Lymphedema	Nov 2, 2022	Rapid Review	Completed	RC1458-000
Oral Feeding for Preterm Infants on Respiratory Support	Oral Feeding for Preterm Infants on Respiratory Support	Oct 31, 2022	Rapid Review	Completed	RC1461-000
Rural Healthcare Planning Initiatives and Frameworks	Rural Healthcare Planning Initiatives and Frameworks	Oct 28, 2022	Health Technology Assessment	Completed	HC0044-000
Intravenous Iron Isomaltoside for Patients with Iron Deficiency Undergoing Elective Surgery	Intravenous Iron Isomaltoside for Patients with Iron Deficiency Undergoing Elec…	Oct 28, 2022	Rapid Review	Completed	RC1456-000
Pediatric Glioma Learning Project	Pediatric Low-Grade Glioma Pre-Meeting Material Pediatric Low-Grade Glioma Multi-stakeholder Dialogue Methods and Practice Repo…Pediatric Low-Grade Glioma Multi-stakeholder Dialogue Lessons Learned Report Scientific Poster	Oct 27, 2022	Technology Review	Active	HM0001-000
Evusheld for the Treatment of Mild to Moderate COVID-19	Evusheld for the Treatment of Mild to Moderate COVID-19	Oct 26, 2022	Technology Review	Completed	HC0041-000
Azacitidine for Acute myeloid leukemia	Azacitidine for Acute myeloid leukemia	Oct 24, 2022	Technology Review	Completed	HC0036-000
Real-Time Continuous Glucose Monitoring: A Review of Guidelines	Real-Time Continuous Glucose Monitoring: A Review of Guidelines	Oct 24, 2022	Summary with Critical Appraisal	Completed	RC1449-000
Treatment Strategies for Sexual Dysfunction Associated With Psychotropic Medications	Treatment Strategies for Sexual Dysfunction Associated With Psychotropic Medica…	Oct 13, 2022	Rapid Review	Completed	RC1455-000
Delayed Tuberculin Skin Testing	Delayed Tuberculin Skin Testing	Oct 7, 2022	Rapid Review	Completed	RC1452-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 111 of 111

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 40 of 40

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 201 - 225 of 2093

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Federal, Provincial, and Territorial Coverage of Diagnostic Sleep Studies		Coverage of Diagnostic Sleep Studies - Draft Coverage of Diagnostic Sleep Studies Infographic - Draft	Nov 5, 2024	Horizon Scan	Environmental Scan	Active	ES0382-000
Utilization of Long-Acting Injectable Antipsychotics			Nov 1, 2024	Health Technology Review	Technology Review	In Progress	HC0098-000
Pharmaceutical Reviews Update — Issue 52			Oct 31, 2024	Reimbursement Review	Pharmaceutical Review Update
epcoritamab		Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation	Oct 31, 2024	Reimbursement Review		Complete	PC0334-000
everolimus		Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Responses to Questions From the Drug Programs Stakeholder Input	Oct 30, 2024	Reimbursement Review		Complete	SX0814-000
rivaroxaban		Recommendation and Reason Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder Input Stakeholder Feedback on Draft Recommendation	Oct 30, 2024	Reimbursement Review		Complete	SX0750-000 - SR0750-000
eltrombopag		Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder Input Stakeholder Feedback on Draft Recommendation	Oct 30, 2024	Reimbursement Review		Complete	SX0777-000
nab-paclitaxel		Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Patient and Clinician Group Input Feedback on Draft Recommendation	Oct 30, 2024	Reimbursement Review		Complete	PX0360-000
Nab-paclitaxel		Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Patient and Clinician Group Input Feedback on Draft Recommendation	Oct 30, 2024	Reimbursement Review		Complete	PX0354-000
Pembrolizumab		Recommendation and Reason Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder Input	Oct 30, 2024	Reimbursement Review		Complete	PX0346-000
Nivolumab and Ipilimumab		Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic combined Report Stakeholder Input	Oct 30, 2024	Reimbursement Review		Complete	PX0347-000
Nab-paclitaxel		Recommendation and reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Patient and Clinician Group Input	Oct 30, 2024	Reimbursement Review		Complete	PX0348-000
panitumumab		Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder input	Oct 30, 2024	Reimbursement Review		Complete	PX0333-000
bevacizumab and lomustine		Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder Input - Clinicians Stakeholder Input - Industry Stakeholder Feedback on Draft Recommendation	Oct 30, 2024	Reimbursement Review		Complete	PX0318-000
Review of Guidelines on Bupropion for Depression		Review of Guidelines on Bupropion for Depression	Oct 30, 2024	Health Technology Review	Rapid Review	Completed	RC1558-000
GLP-1 Receptor Agonists and Self-Harm			Oct 29, 2024	Health Technology Review	Observational Study	Active	OS0009-000
relugolix		Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation Patient and Clinician Group input	Oct 29, 2024	Reimbursement Review		Complete	PC0342-000
Early Biologic Treatment for Inflammatory Bowel Disease		Early Biologic Treatment for Inflammatory Bowel Disease	Oct 25, 2024	Health Technology Review	Rapid Review	Completed	RC1552-000
Gabapentin for Seizures		Gabapentin for Seizures	Oct 25, 2024	Health Technology Review	Rapid Review	Completed	RC1557-000
trametinib		Proposed Scope	Oct 23, 2024	Reimbursement Review		Active	PX0372-000
The Utilization of PCSK9 Inhibitors in Familial Hypercholesterolemia			Oct 22, 2024	Health Technology Review	Technology Review	Active	HC0094-000
baricitinib		Recommendation and Reasons Patient and Clinician Group input	Oct 22, 2024	Reimbursement Review		Active	SR0843-000
CRISPR Technologies for In Vivo and Ex Vivo Gene Editing	Our Horizon Scan provides an overview of CRISPR technologies and their current and potential roles in health care.	Final Report	Oct 21, 2024	Horizon Scan	Emerging Health Technologies	Completed	EH00127-000 - HC0092-000
Airway Management in Out-of-Hospital Emergencies		Airway Management in Out-of-Hospital Emergencies	Oct 21, 2024	Health Technology Review	Rapid Review	Completed	RC1555-000
BRAF and MEK Inhibitors for Active or Symptomatic Melanoma Brain Metastasis		BRAF and MEK Inhibitors for Active or Symptomatic Melanoma Brain Metastasis	Oct 21, 2024	Health Technology Review	Rapid Review	Completed	RC1549-000